2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N16527
    7-O-Galloyl-D-sedoheptulose 233690-85-2
    7-O-Galloyl-D-sedoheptulose is an orally effective polyphenolic compound. 7-O-Galloyl-D-sedoheptulose lowers the serum levels of glucose, leptin, insulin, C-peptide, resistin, TNF-α, IL-6, and increases the serum level of adiponectin. 7-O-Galloyl-D-sedoheptulose significantly reduces the levels of ROS and lipid peroxidation products (TBARS) by down-regulating the protein expression of NADPH oxidase subunit Nox-4 and p22phox. 7-O-Galloyl-D-sedoheptulose down-regulates NF-κB and related pro-inflammatory factors (COX-2, iNOS), inhibits the phosphorylation of JNK and the activity of its downstream AP-1. 7-O-Galloyl-D-sedoheptulose reduces the expression of TGF-β1 and fibronectin, indicating its potential in anti-tissue fibrosis. 7-O-Galloyl-D-sedoheptulose can be used for the study of type 2 diabetes and its hepatic and pancreatic complications.
    7-O-Galloyl-D-sedoheptulose
  • HY-N16529
    1,6,8-Trihydroxy-2,7-dimethoxy-3-methylanthraquinone 2366153-27-5
    1,6,8-Trihydroxy-2,7-dimethoxy-3-methylanthraquinone (Compound 2) is a anthraquinone aglycone found in Cassia obtusefolia. 1,6,8-Trihydroxy-2,7-dimethoxy-3-methylanthraquinone can inhibit α-glucosidase with an IC50 of 120.65 μg/mL. 1,6,8-Trihydroxy-2,7-dimethoxy-3-methylanthraquinone can be used for the research of diabetes.
    1,6,8-Trihydroxy-2,7-dimethoxy-3-methylanthraquinone
  • HY-N16575
    16-Oxoserratenediol 24513-52-8 98%
    16-Oxoserratenediol (Compound 11) is a serratene-type triterpenoid found in Lycopodium cernuum L.. 16-Oxoserratenediol is a α-glucosidase inhibitor with inhibition rate of 43.93% at 100 μM. 16-Oxoserratenediol can be used for the research of diabetes.
    16-Oxoserratenediol
  • HY-N16588
    cis-Emodin-physcion bianthrone 1085706-32-6 98%
    cis-Emodin-physcion bianthrone is a potent inhibitor of protein tyrosine phosphatase 1B (PTP1B), with an IC50 value of 7.29 μM. cis-Emodin-physcion bianthrone can be used for research on type 2 diabetes.
    cis-Emodin-physcion bianthrone
  • HY-N16614
    Ent-Calquiquelignan E 1292294-31-5
    Ent-Calquiquelignan E (Compound 8) is a flavonoid lignan compound. Ent-Calquiquelignan E can selectively inhibit diacylglycerol acyltransferase 1 (DGAT1) with an IC50 of 71.5 μM. Ent-Calquiquelignan E can be used for the research of metabolic diseas.
    Ent-Calquiquelignan E
  • HY-N16617
    Platycodin V 91095-81-7
    Platycodin V is a triterpenoid saponin. Platycodin V has a relatively weak inhibitory effect on pancreatic lipase.
    Platycodin V
  • HY-N16697
    (2R,3S)-Pterosin C 68399-17-7
    (2R,3S)-Pterosin C is a sesquiterpene compound that inhibits triglyceride formation. (2R,3S)-Pterosin C significantly reduces triglyceride levels in 3T3-L1 cells and is used in hyperlipidemia research.
    (2R,3S)-Pterosin C
  • HY-N16751
    Notoginsenoside D 193895-50-0 98%
    Notoginsenoside D is a dammarane-type triterpene oligoglycoside. Notoginsenoside D can be isolated from the dried roots of Panax notoginseng (BURK.) F. H. CHEN. Notoginsenoside D can be used in the research of liver injury.
    Notoginsenoside D
  • HY-N17187
    2,4,6,1'-Tetra-O-acetyl-3',6'-di-O-feruloylsucrose 173614-59-0 98%
    2,4,6,1'-Tetra-O-acetyl-3',6'-di-O-feruloylsucrose (Compound 2) is a phenylpropanoid glycoside that can be found in chinese folk medicine “San Leng” (Sparganium stoloniferum Buch.-Hamil.). San Leng can be used for emmenagogue, galactagogue, and antispasmodic applications.
    2,4,6,1'-Tetra-O-acetyl-3',6'-di-O-feruloylsucrose
  • HY-N17200
    Cyclocarioside K 2093058-16-1 98%
    Cyclocarioside K is a triterpene glycoside compound that can be naturally extracted from the dried leaves of Cyclocarya paliurus (Batal.) Iljinsk (Chinese wingnut) from Bozhou, Anhui, China. The leaves of this plant are traditionally used to lower blood sugar and blood pressure.
    Cyclocarioside K
  • HY-N17215
    3,4,6-Tri-O-galloyl-D-glucose 99523-99-6
    3,4,6-Tri-O-galloyl-D-glucose (3,4,6-Trigalloylglucose) is an α-amylase (porcine α-amylase IC50 = 334.6 μM; Ki = 307.5 μM) and α-glucosidase (yeast α-glucosidase IC50 = 46.5 μM; Ki = 39.9 μM) mixed type inhibitor. 3,4,6-Tri-O-galloyl-D-glucose exhibits free radical scavenging ability, ferric-reducing power, and antioxidant activity. 3,4,6-Tri-O-galloyl-D-glucose can be used for the research of diabetes.
    3,4,6-Tri-O-galloyl-D-glucose
  • HY-N17254
    Onjisaponin R 1008798-85-3
    Onjisaponin R is an α-amylase inhibitor. Onjisaponin R can be used in diabetes research.
    Onjisaponin R
  • HY-N17272
    Cholic acid 3-sulfate 66167-89-3 98%
    Cholic acid 3-sulfate is the sulfated metabolite of Cholic acid (HY-N0324), produced by liver enzyme sulfotransferase-2A1. Cholic acid 3-sulfate is less toxic than the parent compound, thus serving as a detoxification pathway for bile acids. Cholic acid 3-sulfate does not have the effect of stimulating intestinal secretion.
    Cholic acid 3-sulfate
  • HY-N17306
    Loquatifolin A 130466-32-9
    Loquatifolin A is a sesquiterpene glycoside identified in the leaves of loquat (Eriobotrya japonica). Loquatifolin A is applicable to the research of diseases such as non-alcoholic fatty liver disease.
    Loquatifolin A
  • HY-N17317
    Isostrictiniin 1801746-41-7
    Isostrictiniin (ITN) is a polyphenolic compound isolated from Nymphaea candida. It upregulates the expression of Nrf2 and HO-1, while downregulating the expression of Keap1. Isostrictiniin reduces the phosphorylation levels of JNK, ERK1/2, p38, IκBα, and NF-κB p65. Isostrictiniin decreases the levels of pro-inflammatory mediators (IL-1β, IL-6, TNF-α, PGE2). Isostrictiniin alleviates LPS-induced acute lung injury and exerts protective effects against acute alcoholic liver injury. Additionally, isostrictiniin exhibits anti-inflammatory, antioxidant, and anti-fibrotic activities.
    Isostrictiniin
  • HY-N17326
    Ilekudinol B 242794-72-5 98%
    Ilekudinol B is an inhibitor of ACAT and PTP1B, with an IC50 of 5.3 μM and a Ki of 11.6 μM against human PTP1B. Ilekudinol B inhibits the classical pathway of the complement system, with an IC50 of 51 μM. Ilekudinol B inhibits TNF-α-induced cellular IL-8 secretion, promotes glucose uptake in skeletal muscle myotubes, and acts as an insulin mimetic and insulin sensitizer. Ilekudinol B can be used in research related to type 2 diabetes, obesity, and inflammatory diseases.
    Ilekudinol B
  • HY-N17358
    11-Oxo-uvaol 326601-70-1 98%
    11-Oxo-uvaol (compound 15) is a triterpenoid compound that can be found in the leaves of the oxalis chinensis with hypoglycemic effects.
    11-Oxo-uvaol
  • HY-N17375
    Saikosaponin bk1 110352-77-7
    Saikosaponin bk1 is a NADPH-oxidase 5(NOX5) dehydrogenase domain binder and hepatoprotective agent. Saikosaponin bk1 forms stable interactions with the dehydrogenase domain of NOX5 from Cylindrospermum stagnale. Saikosaponin bk1 is applicable to research related to COVID-19 and alcoholic liver injury.
    Saikosaponin bk1
  • HY-N17383
    Ligusticum cycloprolactam 2283387-37-9 98%
    Ligusticum cycloprolactam is a potent, orally active, and CNS-penetrant TLR4/NF-κB inhibitor, exhibiting anti-inflammatory and neuroprotective activity. Ligusticum cycloprolactam reduces FPR1 expression, inhibits NLRP3 inflammasome, TLR4/NF-κB, hepatic MAPK and TGF-β signaling, and selectively activates hepatic FXR. Ligusticum cycloprolactam attenuates pro-inflammatory mediator production, enhances anti-inflammatory cytokine secretion, regulates renal uric acid transporters, and preserves intestinal microbiota composition. Ligusticum cycloprolactam can be used for the research of ischemic stroke, hyperuricemic nephropathy, neuroinflammation, and metabolic dysfunction-associated fatty liver disease.
    Ligusticum cycloprolactam
  • HY-N17411
    1-Dehydroxy-3,4-dihydroaucubigenin 125180-71-4
    1-Dehydroxy-3,4-dihydroaucubigenin is a triglyceride accumulation inhibitor found in taheebo extract from Tabebuia avellanedae. 1-Dehydroxy-3,4-dihydroaucubigenin reduces triglyceride levels in adipocytes without cytotoxicity. 1-Dehydroxy-3,4-dihydroaucubigenin can be used for the research of estrogen deficiency-induced obesity.
    1-Dehydroxy-3,4-dihydroaucubigenin
Cat. No. Product Name / Synonyms Application Reactivity